GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia

Overview of attention for article published in Blood, April 2013

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 21 news outlets
blogs: 1 blog

patent: 2 patents
wikipedia: 3 Wikipedia pages

Readers on

mendeley: 83 Mendeley

So far, Altmetric has seen 40 news stories from 21 outlets.

Taran Therapeutics Reports Publication from PREACH-M Trial for Chronic Myelomonocytic Leukemia in Current Edition of the European Medical Journal

Crwe World, 28 Jul 2025

- Of 34 CMML treatment-naïve participants enrolled and treated with lenzilumab plus azacitidine, 22 have evaluable responses in…

Taran Therapeutics Reports Publication from PREACH-M Trial for Chronic Myelomonocytic Leukemia in Current Edition of the European Medical Journal

Le Lézard, 28 Jul 2025

Classified in: Health, Science and technology - Of 34 CMML treatment-naïve participants enrolled and treated with lenzilumab…

Taran Therapeutics Reports Publication from PREACH-M Trial for Chronic Myelomonocytic Leukemia in Current Edition of the European Medical Journal

Yahoo! Finance USA, 28 Jul 2025

This is a paid. Contact the distributor directly with any inquiries. - Of 34 CMML treatment-naïve participants enrolled and…

Taran Therapeutics Presents Promising Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia and Secondary Acute Myeloid Leukemia Treatment

Crwe World, 21 Jul 2025

- Of 34 CMML treatment-naïve participants enrolled and treated with lenzilumab plus azacitidine, 22 have evaluable responses in…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 36 additional news stories.